文献速递免疫规划传染病防控与疫情报告

荷兰性健康中心就诊的年轻男男性行为者HPV感染:针对性HPV疫苗接种的机会

HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination.
PubMed 文献 · Vaccine · 2020-03-19

研究利用2009-2017年PASSYON横断面数据,分析16-24岁就诊性健康中心的男男性行为者(MSM)HPV DNA和抗体阳性率趋势,发现各疫苗型别生殖器HPV感染率无显著下降,多数MSM对疫苗型别DNA和血清学双阴性,提示针对该人群接种HPV疫苗仍可能有益。

要点

  • 2009-2017年荷兰仅女孩接种HPV16/18疫苗后,MSM各疫苗型别HPV感染率无显著变化。
  • 575名MSM中,79%阴茎和肛门HPV16/18 DNA双阴性,62%HPV6/11/16/18双阴性,53%九价疫苗型别双阴性。
  • HPV16/18 DNA阴性且检测血清者中82%血清阴性,九价型别DNA阴性者中71%血清阴性。

核心结论

  • 仅女孩接种HPV16/18疫苗后八年内,MSM的HPV感染率无显著下降,MSM不太可能从仅女孩接种的群体免疫中大幅获益。
  • 多数就诊性健康中心的年轻MSM对疫苗型别DNA和血清学双阴性,提示对该人群接种HPV疫苗仍可能有益。

研究设计与样本

  • 利用PASSYON研究2009-2017年数据,为每两年一次、针对16-24岁性健康中心就诊者的横断面研究。
  • 共纳入575名MSM,中位年龄22岁,中位终身性伴侣数15,HIV阳性率3.5%。
  • MSM提供阴茎和肛门拭子进行HPV DNA检测(包含HPV6/11/16/18/31/33/45/52/58),并提供血液进行HPV抗体检测(HPV16/18/31/33/45/52/58)。

主要发现

  • 2009-2017年阴茎或肛门HPV感染率趋势对所有疫苗型别均无统计学显著性。
  • 455名有阴茎和肛门拭子的MSM中,360名(79%)对HPV16/18双部位DNA阴性,283名(62%)对HPV6/11/16/18双阴性,242名(53%)对HPV6/11/16/18/31/33/45/52/58双阴性。
  • HPV16/18 DNA阴性且检测血清者(n=335)中82%血清阴性,HPV16/18/31/33/45/52/58 DNA阴性且检测血清者(n=279)中71%血清阴性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2009, girls-only HPV16/18 vaccination was introduced in the Netherlands which has achieved 46-61% uptake. Heterosexual men have benefitted from herd protection, but it is unknown whether men who have sex with men (MSM) also benefit from herd effects of the girls-only HPV16/18 vaccination program. Because MSM bear a high HPV-related disease burden, countries might consider targeted vaccination for MSM. To study possible herd effects and prior HPV exposure at a potential moment of vaccination, we assessed trends in the HPV prevalence and proportions (sero)negative for the various vaccine types among young MSM visiting sexual health centers (SHCs). METHODS: We used data from MSM included in PASSYON study years 2009-2017. In this biennial cross-sectional study among visitors of SHCs aged 16-24 years, MSM provided a penile and anal swab for HPV DNA testing (including vaccine types HPV6/11/16/18/31/33/45/52/58) and blood for HPV antibody testing (HPV16/18/31/33/45/52/58). RESULTS: In total 575 MSM were included, with a median of 22 years of age and 15 lifetime sex partners and 3.5% HIV positive. Trends in penile or anal HPV prevalence during 2009-2017 were statistically non-significant for all vaccine types. Of the 455 MSM with a penile and anal swab, 360 (79%), 283 (62%) and 242 (53%) were HPV DNA negative at both anatomical sites for HPV16/18, HPV6/11/16/18 and HPV6/11/16/18/31/33/45/52/58 respectively. Among MSM who were HPV16/18 and HPV16/18/31/33/45/52/58 DNA negative and were tested for serology (n = 335 and 279 respectively), 82% and 71% were also seronegative for the respective types. DISCUSSION: There were no significant declines in the HPV prevalence among MSM up to eight years after introduction of girls-only HPV16/18 vaccination, indicating that MSM are unlikely to benefit largely from herd effects from girls-only vaccination. Most MSM were vaccine-type DNA negative and seronegative, suggesting that vaccination of young MSM visiting SHCs could still be beneficial.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Woestenberg PJ, van Benthem BHB, Bogaards JA, et al. HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination. Vaccine. 2020. PMID: 32201140. doi:10.1016/j.vaccine.2020.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。